Xiliarx Evropska unija - slovenščina - EMA (European Medicines Agency)

xiliarx

novartis europharm limited - vildagliptin - diabetes mellitus, tip 2 - zdravila, ki se uporabljajo pri diabetesu - vildagliptin is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus:as monotherapy in patients in whom metformin is inappropriate due to contraindications or intolerance. in combination with other medicinal products for the treatment of diabetes, including insulin, when these do not provide adequate glycaemic control (see sections 4. 4, 4. 5 in 5. 1 za razpoložljive podatke o različnih kombinacijah).

Aimovig Evropska unija - slovenščina - EMA (European Medicines Agency)

aimovig

novartis europharm limited - erenumab - bolezni migrene - analgetiki - aimovig je označen za preventivo migrena pri odraslih, ki imajo vsaj 4 migrenskih dni v mesecu, ko začetkom zdravljenja z aimovig.

Reasanz Evropska unija - slovenščina - EMA (European Medicines Agency)

reasanz

novartis europharm ltd - serelaxin - odpoved srca - drugi vasodilators ki se uporabljajo v srčni bolezni - zdravljenje akutnega srčnega popuščanja.

Zelnorm Evropska unija - slovenščina - EMA (European Medicines Agency)

zelnorm

novartis europharm limited - tegaserod - sindrom razdražljivega črevesa - zdravila za funkcionalne prebavne motnje - zelnorm je primerna za večkratno simptomatsko kratkotrajno zdravljenje žensk z sindrom razdražljivega Črevesja (ibs), katerih prevladujoča črevesja navada je, zaprtje, povezane z trebušne bolečine/nelagodje ali napihnjenost (glej poglavje 4.

Beovu Evropska unija - slovenščina - EMA (European Medicines Agency)

beovu

novartis europharm limited  - brolucizumab - mokra makularna degeneracija - oftalmologi - beovu je navedeno pri odraslih za zdravljenje neovascular (mokro) starostna degeneracija rumene pege (amd).

Enerzair Breezhaler Evropska unija - slovenščina - EMA (European Medicines Agency)

enerzair breezhaler

novartis europharm limited - indacaterol, glycopyrronium bromide, mometasone - astma - zdravila za obstruktivne pljučne bolezni, - enerzair breezhaler is indicated as a maintenance treatment of asthma in adult patients not adequately controlled with a maintenance combination of a long acting beta2 agonist and a high dose of an inhaled corticosteroid who experienced one or more asthma exacerbations in the previous year.

Bemrist Breezhaler Evropska unija - slovenščina - EMA (European Medicines Agency)

bemrist breezhaler

novartis europharm limited  - indacaterol, mometasone furoate - astma - zdravila za obstruktivne pljučne bolezni, - bemrist breezhaler is indicated as a maintenance   treatment of asthma in adults and adolescents 12 years of age and older not adequately controlled with inhaled corticosteroids and inhaled short acting beta2-agonists.

Zimbus Breezhaler Evropska unija - slovenščina - EMA (European Medicines Agency)

zimbus breezhaler

novartis europharm limited - glycopyrronium bromide, indacaterol (acetate), mometasone furoate - astma - zdravila za obstruktivne pljučne bolezni, - maintenance treatment of asthma in adults whose disease is not adequately controlled.

Leqvio Evropska unija - slovenščina - EMA (European Medicines Agency)

leqvio

novartis europharm limited - inclisiran - hypercholesterolemia; dyslipidemias - sredstva za spreminjanje lipidov - leqvio is indicated in adults with primary hypercholesterolaemia (heterozygous familial and non-familial) or mixed dyslipidaemia, as an adjunct to diet:in combination with a statin or statin with other lipid-lowering therapies in patients unable to reach ldl-c goals with the maximum tolerated dose of a statin, oralone or in combination with other lipid-lowering therapies in patients who are statin-intolerant, or for whom a statin is contraindicated.

Tabrecta Evropska unija - slovenščina - EMA (European Medicines Agency)

tabrecta

novartis europharm limited  - capmatinib dihydrochloride monohydrate - karcinom, pljučni pljuč - antineoplastična sredstva - tabrecta as monotherapy is indicated for the treatment of adult patients with advanced non small cell lung cancer (nsclc) harbouring alterations leading to mesenchymal epithelial transition factor gene exon 14 (metex14) skipping, who require systemic therapy following prior treatment with immunotherapy and/or platinum based chemotherapy.